Hepatology
Research activity is centered on chronic hepatitis B, with clinical interest in disease control among participants receiving nucleoside analogues.
- Chronic hepatitis B
- Viral hepatitis
- Hepatic infection
The sponsor’s clinical work in this area reflects a focused interest in therapies aimed at improving outcomes in persistent HBV infection.
Antiviral Therapy
Clinical development is directed toward an investigational treatment intended for use alongside background antiviral management in chronic hepatitis B.
- Antiviral treatment
- HBV suppression
- Combination therapy
This area of interest includes therapies designed to complement established nucleos(t)ide analogue treatment in patients with ongoing viral disease.
Immunology
The sponsor’s research also involves immune-targeted approaches relevant to hepatitis B, including evaluation of immunogenicity in treated participants.
- Immunogenicity
- Immune response
- Therapeutic antibodies
These interests align with strategies that seek to influence the host response in chronic viral liver disease.
Clinical Pharmacology
Current research includes assessment of pharmacokinetics and treatment-related safety characteristics for an investigational injection used in chronic hepatitis B.
- Pharmacokinetics
- Safety evaluation
- Injectable biologics
The sponsor’s clinical portfolio in this field is concentrated on therapeutic properties relevant to systemic administration in viral liver disease.
